The French Company Sanofi Will Begin Testing A Vaccine Against Coronavirus In September
The French pharmaceutical Corporation Sanofi plans to start clinical trials of a vaccine against the new coronavirus in September this year and release it on sale in the first half of 2021.
Sanofi assures that the vaccine will be "effective and reliable" and will be produced in large volumes. According to Sanofi CEO Paul Hudson, speaking about the strong competition in the field of creating a coronavirus vaccine, the company he leads "acts slower than competitors, but at the same time has a greater chance of success than they do."
This is a vaccine being developed jointly with the British company GSK and based on DNA recombination technology, which is already used in the creation of anti-influenza vaccines. Sanofi believes that the Corporation will be able to produce up to 1 billion doses per year if the vaccine is successfully tested.
At the same time, Sanofi is developing another coronavirus vaccine in collaboration with the biotechnology company Translate Bio. This vaccine is created by transferring a fragment of RNA, the genetic code of the virus. Еhe first phase of clinical trials is planned for the period until the end of the year for this vaccine. If successful, the company hopes to certify it in the second half of 2021 and produce between 90 million and 360 million doses per year in the future.